High Prevalence of Antimicrobial Resistance Among Shigella Isolates in the United States Tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2005 Dec 27

PMID 16377666

Citations 38

Authors

Sumathi Sivapalasingam

Jennifer M Nelson

Kevin Joyce

Mike Hoekstra

Frederick J Angulo

Eric D Mintz

Affiliations

Soon will be listed here.

Abstract

Shigella spp. infect approximately 450,000 persons annually in the United States, resulting in over 6,000 hospitalizations. Since 1999, the National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria has tested every 10th Shigella isolate from 16 state or local public health laboratories for susceptibility to 15 antimicrobial agents. From 1999 to 2002, NARMS tested 1,604 isolates. Among 1,598 isolates identified to species level, 1,278 (80%) were Shigella sonnei, 295 (18%) were Shigella flexneri, 18 (1%) were Shigella boydii, and 7 (0.4%) were Shigella dysenteriae. Overall, 1,251 (78%) were resistant to ampicillin and 744 (46%) were resistant to trimethoprim-sulfamethoxazole (TMP-SMX). Prevalence of TMP-SMX- or ampicillin- and TMP-SMX-resistant Shigella sonnei isolates varied by geographic region, with lower rates in the South and Midwest regions (TMP-SMX resistance, 27% and 30%, respectively; ampicillin and TMP-SMX resistance, 25% and 22%, respectively) and higher rates in the East and West regions (TMP-SMX resistance, 66% and 80%, respectively; ampicillin and TMP-SMX resistance, 54% and 65%, respectively). Nineteen isolates (1%) were resistant to nalidixic acid (1% of S. sonnei and 2% of S. flexneri isolates); 12 (63%) of these isolates had decreased susceptibility to ciprofloxacin. One S. flexneri isolate was resistant to ciprofloxacin. All isolates were susceptible to ceftriaxone. Since 1986, resistance to ampicillin and TMP-SMX has dramatically increased. Shigella isolates in the United States remain susceptible to ciprofloxacin and ceftriaxone.

Citing Articles

Characterizations of novel broad-spectrum lytic bacteriophages and infecting MDR spp. with their application on raw chicken to reduce the load.

Ahamed S, Rai S, Guin C, Jameela R, Dam S, Muthuirulandi Sethuvel D Front Microbiol. 2023; 14:1240570.

PMID: 38094623 PMC: 10716491. DOI: 10.3389/fmicb.2023.1240570.

Clinical Prediction Rule to Guide Diagnostic Testing for and Improve Antibiotic Stewardship for Pediatric Diarrhea.

Ahmed S, Brintz B, Pavlinac P, Hossain M, Khan A, Platts-Mills J Open Forum Infect Dis. 2023; 10(3):ofad119.

PMID: 36998629 PMC: 10043128. DOI: 10.1093/ofid/ofad119.

[Shigellosis attended in the emergency department of a regional hospital in southeastern Spain: from their presence to multiresistance].

Rodriguez-Guerrero E, Herrera-Leon S, Gomez-Vicente E, Navarro-Mari J, Gutierrez-Fernandez J Rev Esp Quimioter. 2023; 36(3):282-290.

PMID: 36942425 PMC: 10238789. DOI: 10.37201/req/121.2022.

Changing epidemiology of shigellosis in Taiwan, 2010-2019: an emerging threat to HIV-infected patients and men who have sex with men.

Tsai C, Lin K, Liou B, Chiou C, Lin Y, Lee Y Emerg Microbes Infect. 2022; 11(1):498-506.

PMID: 35045788 PMC: 8855726. DOI: 10.1080/22221751.2022.2031309.

Screening of anti-microbial, anti-biofilm activity, and cytotoxicity analysis of a designed polyherbal formulation against shigellosis.

Singh D, Sharma D, Agarwal V J Ayurveda Integr Med. 2021; 12(4):601-606.

PMID: 34772585 PMC: 8642668. DOI: 10.1016/j.jaim.2021.06.007.

References

Baer J, Vugia D, Reingold A, Aragon T, Angulo F, BRADFORD W . HIV infection as a risk factor for shigellosis. Emerg Infect Dis. 1999; 5(6):820-3. PMC: 2640795. DOI: 10.3201/eid0506.990614. View

Huang I, Chiu C, Wang M, Wu C, Hsieh K, Chiou C . Outbreak of dysentery associated with ceftriaxone-resistant Shigella sonnei: First report of plasmid-mediated CMY-2-type AmpC beta-lactamase resistance in S. sonnei. J Clin Microbiol. 2005; 43(6):2608-12. PMC: 1151904. DOI: 10.1128/JCM.43.6.2608-2612.2005. View

Leibovitz E, JANCO J, Piglansky L, Press J, Yagupsky P, Reinhart H . Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J. 2000; 19(11):1060-7. DOI: 10.1097/00006454-200011000-00006. View

Dunne E, Fey P, Kludt P, Reporter R, Mostashari F, Shillam P . Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase. JAMA. 2001; 284(24):3151-6. DOI: 10.1001/jama.284.24.3151. View

Guerrant R, Van Gilder T, Steiner T, Thielman N, Slutsker L, Tauxe R . Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001; 32(3):331-51. DOI: 10.1086/318514. View

Fortineau N, Naas T, Gaillot O, Nordmann P . SHV-type extended-spectrum beta-lactamase in a Shigella flexneri clinical isolate. J Antimicrob Chemother. 2001; 47(5):685-8. DOI: 10.1093/jac/47.5.685. View

Radice M, Gonzealez C, Power P, Vidal M, Gutkind G . Third-generation cephalosporin resistance in Shigella sonnei, Argentina. Emerg Infect Dis. 2001; 7(3):442-3. PMC: 2631805. DOI: 10.3201/eid0703.010313. View

Pai H, Choi E, Lee H, Hong J, Jacoby G . Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J Clin Microbiol. 2001; 39(10):3747-9. PMC: 88424. DOI: 10.1128/JCM.39.10.3747-3749.2001. View

. Shigella sonnei outbreak among men who have sex with men--San Francisco, California, 2000-2001. MMWR Morb Mortal Wkly Rep. 2001; 50(42):922-6. View

10.

Sarkar K, Ghosh S, Niyogi S, Bhattacharya S . Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones. Lancet. 2003; 361(9359):785. DOI: 10.1016/s0140-6736(03)12644-x. View

11.

Sur D, Niyogi S, Sur S, Datta K, Takeda Y, Nair G . Multidrug-resistant Shigella dysenteriae type 1: forerunners of a new epidemic strain in eastern India?. Emerg Infect Dis. 2003; 9(3):404-5. PMC: 2958544. DOI: 10.3201/eid0903.020352. View

12.

Shane A, Tucker N, Crump J, Mintz E, Painter J . Sharing Shigella: risk factors for a multicommunity outbreak of shigellosis. Arch Pediatr Adolesc Med. 2003; 157(6):601-3. DOI: 10.1001/archpedi.157.6.601-b. View

13.

Acikgoz Z, Gulay Z, Bicmen M, Gocer S, Gamberzade S . CTX-M-3 extended-spectrum beta-lactamase in a Shigella sonnei clinical isolate: first report from Turkey. Scand J Infect Dis. 2003; 35(8):503-5. DOI: 10.1080/00365540310013270. View

14.

. Day care-related outbreaks of rhamnose-negative Shigella sonnei--six states, June 2001-March 2003. MMWR Morb Mortal Wkly Rep. 2004; 53(3):60-3. View

15.

Talukder K, Khajanchi B, Islam M, Dutta D, Islam Z, Safa A . Genetic relatedness of ciprofloxacin-resistant Shigella dysenteriae type 1 strains isolated in south Asia. J Antimicrob Chemother. 2004; 54(4):730-4. DOI: 10.1093/jac/dkh425. View

16.

Naheed A, Kalluri P, Talukder K, Faruque A, Khatun F, Nair G . Fluoroquinolone-resistant Shigella dysenteriae type 1 in northeastern Bangladesh. Lancet Infect Dis. 2004; 4(10):607-8. DOI: 10.1016/S1473-3099(04)01143-0. View

17.

Nelson J, Kusmiesz H, Jackson L, Woodman E . Trimethoprim-sulfamethoxazole therapy for shigellosis. JAMA. 1976; 235(12):1239-43. View

18.

Olarte J, FILLOY L, Galindo E . Resistance of Shigella dysenteriae type 1 to ampicillin and other antimicrobial agents: strains isolated during a dysentery outbreak in a hospital in Mexico City. J Infect Dis. 1976; 133(5):572-5. DOI: 10.1093/infdis/133.5.572. View

19.

Vaudaux P, Waldvogel F . Gentamicin antibacterial activity in the presence of human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1979; 16(6):743-9. PMC: 352946. DOI: 10.1128/AAC.16.6.743. View

20.

Khan M . Interruption of shigellosis by hand washing. Trans R Soc Trop Med Hyg. 1982; 76(2):164-8. DOI: 10.1016/0035-9203(82)90266-8. View